Skip to main
  1. Stocks
  2. Vir Biotechnology
  3. Forecast
VIR

Vir Biotechnology (VIR) Stock Forecast & Price Target

Vir Biotechnology (VIR) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vir Biotechnology is supported by a highly derisked HDV franchise, as ECLIPSE 1 met both the Week 48 composite endpoint and the key virologic endpoint, with 44.1% achieving TND plus ALT normalization and 79.2% reaching TND, while safety remained clean with no SAEs or discontinuations. The depth of suppression, plus encouraging finite-therapy data from SOLSTICE showing all 10 selected patients maintained SVR12 after stopping treatment, strengthens the case for a differentiated, potentially best-in-disease regimen and supports the planned mid-2027 FDA submission. Beyond HDV, the company has multiple catalysts in oncology, including VIR-5500 advancing to pivotal Ph3 trials in 2027 and partnered programs that could expand the commercial opportunity, while current revenue is still mainly from licensing rights and grants.

Bears say

Vir Biotechnology is exposed to substantial development, regulatory, and manufacturing risk, and its clinical-stage pipeline may fail to demonstrate safety and efficacy in trials, which is especially concerning for programs like tobevibart + elebsiran and VIR-5818. The company also faces intense competition in HDV and TCE therapeutics, while its reliance on license rights and grants suggests limited operating durability and a likely need to raise additional capital to fund long, expensive development timelines. Added pressure comes from FDA change requests that delayed VIR-5818 data release, underscoring execution risk, and from uncertain intellectual property protection that could weaken commercialization prospects.

Vir Biotechnology (VIR) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vir Biotechnology and is not a guaranteed prediction by Public.com or investment advice.

Vir Biotechnology (VIR) Analyst Forecast & Price Prediction

Get the latest Vir Biotechnology (VIR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Vir Biotechnology (VIR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vir Biotechnology (VIR) Forecast

Analysts have given Vir Biotechnology (VIR) a Buy based on their latest research and market trends.

According to 6 analysts, Vir Biotechnology (VIR) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vir Biotechnology (VIR)


Vir Biotechnology (VIR) Analyst Forecast & Price Prediction

Get the latest Vir Biotechnology (VIR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Vir Biotechnology (VIR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover VIR stock data and trends